• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Want a Dash for Trash? Why Not Look at Alkermes

Sometimes, buying low can work as a balance, almost a strange sort of diversification.
By TIMOTHY COLLINS
Aug 15, 2016 | 10:00 AM EDT
Stocks quotes in this article: ALKS

Sometimes when things get high, you have to look low. Chasing market highs can feel wrong for some. Quite frankly, there are few things more bullish than a new high; however, it comes with emotional stress for many traders.

No one wants to top tick a stock, and corrections can be painful from the highest levels. Sometimes buying low can work as a balance, almost a strange sort of diversification. It isn't a diversification as defined by the traditional sense of the word, of course, but beaten-down stocks can often act differently in a market pushing new highs, whether those gains continue or we see some sort of correction.

A dash for trash, a play on stocks "due" to revert to the mean, or simply a belief bad news is already priced in all lend support to this trading thesis.

Let's take Alkermes (ALKS) as an example. Granted, the daily chart doesn't look that bad in terms of price over the past four months. The chart runs from lower left to upper right, which is what any bullish trader wants to see.

The issue comes in the secondary technical indicators, those away from price. Price has been trending lower, although I could argue it as a bullish flag coming into support here at the 50-day moving average (SMA). This is the purple shaded area.

Only once has the stock violated this level significantly since the beginning of April, and it only maintained a price below the 50-day SMA for a single day. This recent pullback though has been enough to push the StochRSI and Full Stochastics into oversold territory.

Now, we are seeing a potential crossover in the Full Stochastics while under 30. A crossover along with the StochRSI moving out of oversold territory has been bullish for the price action in the following few weeks. The risk-reward here is interesting, as the upside on a close over $47.75 looks to be around $52, while the $44 level, if not a bit higher, looks to be a clear stop level.

A buying trigger isn't far off in terms of price, the StochRSI, and the Full Stochastics, so keep an eye peeled here for a swing trade.

Pushing out to a weekly view, we can see the damage failed trials caused in January. The stock is still well off those highs, even with this recent rally in the falling wedge pattern.

Upside here again aligns with the daily chart, although I might put it at $55 rather than $52. ALKS is right on support here, with the 13-week SMA and the lower portion of the rising wedge aligning with current price.

Again, I wouldn't give this room under $44, so our stop and targets hold similar risk vs. reward properties. I will say the weekly chart isn't as enticing as the daily chart, due to the failing technicals that are more bullish in nature, but in the end I would let price dictate entry.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Tim Collins had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | How-to | Stocks

More from Healthcare

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

It's an Opportune Time to Renew Your Vows With CVS Health

Paul Price
Feb 18, 2021 7:00 AM EST

The pharmacy giant offered a great buy/write options play last summer and is setting up again for such action.

Just Had My First Teladoc Appointment: Is the Rally Over?

Bruce Kamich
Feb 17, 2021 2:39 PM EST

I may be late to trends, but not to stock charts.

CVS Health Reports Q4, and Here's What I'm Changing Up

Stephen Guilfoyle
Feb 16, 2021 10:55 AM EST

I do want to give new CEO Karen Lynch a chance. Nothing against Larry Merlo but I always thought that this stock was undervalued.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • 12:31 PM EST GARY BERMAN

    Has the Short-Term Top Come for the XLF/Banks?

    The has triggered a long-term overbought signal ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login